AZTA stock touches 52-week low at $38.78 amid market shifts

Published 12/03/2025, 15:00
AZTA stock touches 52-week low at $38.78 amid market shifts

In a challenging economic climate, AZTA stock has reached a 52-week low, dipping to $38.78. According to InvestingPro analysis, the stock appears undervalued at current levels, with three analysts recently revising their earnings expectations upward. This price movement reflects broader market trends and investor sentiment that have impacted the stock over the past year. Notably, Brooks Automation (NASDAQ:AZTA), the parent company of AZTA, has experienced a significant 1-year change, with its stock value declining by 37.69%. This downturn mirrors the volatility and headwinds faced by the sector, as companies navigate through a complex mix of supply chain issues, regulatory changes, and shifting demand patterns. Investors are closely monitoring these developments as they assess the long-term prospects of AZTA and its parent company. The company maintains a GOOD financial health score, with more cash than debt on its balance sheet. Get access to 10+ additional exclusive ProTips and a comprehensive Research Report for AZTA through InvestingPro.

In other recent news, Azenta, Inc. reported positive first-quarter results with revenue and earnings per share surpassing expectations. This performance prompted Jefferies to raise its price target for Azenta to $52, citing signs of an operational turnaround and progress in the sale of the B Medical (TASE:BLWV) Systems segment. Needham also increased its price target to $59, maintaining a Buy rating, and noted that Azenta’s adjusted EBITDA aligned with expectations, with potential for future upside. The company has classified its B Medical Systems segment as a discontinued operation, reflecting a strategic shift to focus on its core Sample Management Solutions and Multiomics businesses. TD Cowen began coverage on Azenta with a Hold rating and a $50 price target, acknowledging the company’s restructuring efforts and the competitive pressures it faces. Analysts from Jefferies and Needham have highlighted the challenges from China tariffs and NIH funding but believe these are factored into Azenta’s growth guidance. Azenta’s management is focused on streamlining operations and concentrating resources on higher-margin segments. The company’s future prospects remain under observation as it navigates these strategic changes and market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.